BEAT vs. XAIR, APYX, DXR, CTSO, AMIX, HSAQ, CTCX, SRTS, NSPR, and LUCD
Should you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include Beyond Air (XAIR), Apyx Medical (APYX), Daxor (DXR), Cytosorbents (CTSO), Autonomix Medical (AMIX), Health Sciences Acquisitions Co. 2 (HSAQ), Carmell (CTCX), Sensus Healthcare (SRTS), InspireMD (NSPR), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.
BioTelemetry (NASDAQ:BEAT) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.
BioTelemetry presently has a consensus price target of $6.78, suggesting a potential upside of 237.06%. Beyond Air has a consensus price target of $11.25, suggesting a potential upside of 951.40%. Given Beyond Air's higher possible upside, analysts plainly believe Beyond Air is more favorable than BioTelemetry.
BioTelemetry has a beta of -1.23, indicating that its share price is 223% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500.
BioTelemetry received 345 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.25% of users gave Beyond Air an outperform vote while only 63.71% of users gave BioTelemetry an outperform vote.
BioTelemetry has higher earnings, but lower revenue than Beyond Air. BioTelemetry is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
BioTelemetry's return on equity of -106.91% beat Beyond Air's return on equity.
7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 7.3% of BioTelemetry shares are owned by insiders. Comparatively, 19.0% of Beyond Air shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, BioTelemetry and BioTelemetry both had 2 articles in the media. Beyond Air's average media sentiment score of 1.53 beat BioTelemetry's score of 0.00 indicating that Beyond Air is being referred to more favorably in the news media.
Summary
Beyond Air beats BioTelemetry on 9 of the 14 factors compared between the two stocks.
Get BioTelemetry News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioTelemetry Competitors List
Related Companies and Tools
